Histological Analysis Shows That a Moisturizer Formulated for Dermatoporosis Increases Elastin Content and Improves Skin Elasticity.

J Drugs DermatolOct 1, 2026
Clinical ResearchDermatologyPathology (Anatomic & Clinical)

Glynis Ablon, Todd Schlesinger, Christine Emesiani et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter clinical trial evaluated the effects of a novel moisturizer (GC cream) on skin biomarkers in individuals aged 40 to 60 with dermatoporosis. After 12 weeks of application, elastin expression significantly increased from 18% to 36% (P<.05), indicating improved skin elasticity and texture.

Key findings

  • Elastin expression increased from 18% to 36% after 12 weeks of GC cream use (P<.05).
  • Beta-galactosidase expression trended higher from 18% to 24% over the study period.
  • Skin firmness and appearance showed visible improvement after treatment.

Why it matters

The study highlights the potential of topical moisturizers to enhance skin health in aging populations, addressing common issues associated with dermatoporosis. Improved elastin levels may contribute to better skin elasticity and overall appearance.

Source

PubMed · PMID 42826145

Published in J Drugs Dermatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.